Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd announced a settlement and license agreement...
In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild de...
Certara, Inc. a global leader in model-informed drug development, announced the launch of its Non-Animal Navigator™ solution designed to help bi...
Lonza joined CMAC to enhance its service offering for specialty and enhanced drug product and particle technologies Lonza will ser...
Mabion S.A. ("Mabion"), a leading Polish CDMO specializing in the development and manufacturing of biopharmaceuticals for third parties, and Instituto de B...
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that results from a Phase 3 registrational clinical study evaluating...
Approval based on Phase III STARGLO study where Columvi in combination with chemotherapy showed a 41% reduction in the risk of death compared to MabThe...
Vantage Biosciences is a clinical-stage biotechnology company developing innovative therapies for the treatment of diabetic eye diseases. The company ...
Odylia Therapeutics (Odylia) a nonprofit biotechnology company dedicated to expediting drug development for rare diseases, hosted a Rare Disease Day event ...
Idorsia Ltd announced the publication of "Aprocitentan for Blood Pressure Reduction in Black Patients” in the April edition of Hypertensio...
Shilpa Medicare announces that Shilpa Pharma Lifesciences – a wholly owned subsidiary – has successfully passed a U.S. Food and Drug Admin...
GC Biopharma announced 09. Apr. 2025 that the Korean Ministry of Food and Drug Safety (MFDS) has approved its anthrax vaccine, BARYTHRAX, jointly develop...
Gift of Life Biologics, a leading supplier of high-quality cellular starting materials in the US, and Cellex Cell Professionals, a trusted Contract De...
NeuroSense Therapeutics, a leading clinical-stage biotechnology company focused on developing treatments for severe neurodegenerative diseases, announced t...
© 2025 Biopharma Boardroom. All Rights Reserved.
